clinical_trials
Novel GLP-1 Cut Heavy Drinking Days in Alcohol Use Disorder
Confidence86·multiple reportsImportance88NP-EVT-20261112-A4DCDC1
(MedPage Today) -- The investigational glucagon/GLP-1 dual receptor agonist pemvidutide significantly reduced the number of heavy drinking days (HDDs) per week in patients with moderate-to-severe alcohol use disorder (AUD), the phase II RECLAIM...
Read the original at the primary source
Novel GLP-1 Cut Heavy Drinking Days in Alcohol Use Disorder
11/12/2026, 4:42:57 PM
Also on the network: airlinesairports · farmerspulse · foodpulse · indianhealthpulse · indias · keralahealth · naturepulse · travelerpulse
Discussion
ChatsPulse · 0 threads
No discussion yet. Sign in and start the first thread —